- Mireia Córcoles
- No Comments
The Cellers Maset grant will fund a research project for minority diseases every year
Researchers Laura Valdesoiro and Roser Ayats collected the scholarship in an event organized this Tuesday at Parc Taulí
This Tuesday, April 25, the delivery ceremony of the first Pau Massana Scholarship for research into minority diseases de Maset Cellars, which will make it possible to annually finance a research project of the Parc Taulí Research and Innovation Institute (I3PT).
El winning project of this first edition was "Effect of ivacaftor/tezacaftor/elexacaftor at pulmonary, nutritional and metabolic level in cystic fibrosis in a reference unit", led by Laura Valdesiro i Rose Ayats, principal researchers of the research group of Cystic Fibrosis of the I3PT.
The event had the presentation of Paco García, president of theCatalan Association of Cystic Fibrosis, who has told how it is daily life of patients with Cystic Fibrosis, and all the challenges they face in their day-to-day lives due to suffering from this disease. "The lives of these people revolve around four axes: physiotherapy, nutrition, antibiotic therapy and adherence to treatments."
La researcher Sara Bajja, collaborator of the Institute's CF research group, has presented the latest developments in pathology research. Specifically, Bajja explained the results of the studies on the effect of CFTR modulators. "If the results are maintained over time, they will represent the greatest therapeutic advance in the history of this disease."
La Pau Massana scholarship is an initiative of Cellers Maset in collaboration with the I3PT to raise funds and contribute €25.000 each year for the research of diseases of low or very low prevalence in society To reach this amount, the winery put 2.500 bottles of its Solidari cava on sale.
The name of the scholarship is a heartfelt tribute to the youngest son of the Massana family, Pau, who at the beginning of 2000 suffered from a rare lung disease.
You might also like
I3PT, CONNECTA Therapeutics, CRG and IMIM receive 2,7 million from the Ministry of Science and Innovation to start Phase IIa of the drug CTH120 for fragile X syndromeI3PT, CONNECTA Therapeutics, CRG and IMIM receive 2,7 million from the Ministry of Science and Innovation to start Phase IIa of the drug CTH120 for fragile X syndrome https://www.tauli.cat/institut/wp-content/uploads/2024/02/Plantilla-Imatges-Web-169-1200x675.jpg 1080 608 Mireia Córcoles Mireia Córcoles https://www.tauli.cat/institut/wp-content/uploads/2022/11/Tezza-0184-150x150.jpg
The I3PT wins 2 scholarships from the Ministry for a value of more than 700.000 eurosThe I3PT wins 2 scholarships from the Ministry for a value of more than 700.000 euros https://www.tauli.cat/institut/wp-content/uploads/2024/01/ResolucioConvocatories-1200x675.jpg 1080 608 Oriol Capell Oriol Capell https://secure.gravatar.com/avatar/97c9519819f851a011f17a028acac50c?s=96&d=mm&r=g
Parc Taulí organizes the first European Workshop on Angelman Syndrome in CataloniaParc Taulí organizes the first European Workshop on Angelman Syndrome in Catalonia https://www.tauli.cat/institut/wp-content/uploads/2023/07/Plantilla-Imatges-169-Web-1-1200x675.png 1080 608 Mireia Córcoles Mireia Córcoles https://www.tauli.cat/institut/wp-content/uploads/2022/11/Tezza-0184-150x150.jpg